Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Pass Below Two Hundred Day Moving Average – What’s Next?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $31.25 and traded as low as $27.50. Lakefront Biotherapeutics American Depositary Shares shares last traded at $28.11, with a volume of 148,929 shares changing hands.

Analysts Set New Price Targets

A number of research firms recently commented on LKFT. Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research cut Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Royal Bank Of Canada increased their price objective on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 24th. Finally, UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Price Performance

The firm’s fifty day simple moving average is $28.38 and its 200 day simple moving average is $31.25. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -19.94 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The firm had revenue of $1.06 billion for the quarter. Equities research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 2.1% in the third quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock worth $1,072,000 after buying an additional 643 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 3.7% during the 3rd quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 800 shares during the last quarter. State of Wyoming bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter valued at approximately $28,000. Finally, Arax Advisory Partners lifted its holdings in Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,778 shares during the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.